Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

741
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

552
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
552
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

553
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
553
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment effects in contemporary cardiovascular pharmacotherapy: determinants and interpretation.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Diuretic dose and right atrial function interplay in patients with tricuspid regurgitation.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026
Same author

Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics.

European cardiology·2026
Same author

Artificial Intelligence in Biomedical Scientific Publishing.

European heart journal·2026
Same author

Antidotes for Anticoagulation Reversal.

The New England journal of medicine·2026
Same author

Innovation and constraints in cardiovascular pharmacotherapy.

European heart journal. Cardiovascular pharmacotherapy·2026

Related Experiment Video

Updated: Jul 15, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.7K

Oral Anticoagulants Beyond Warfarin.

Renske H Olie1, Kristien Winckers1, Bianca Rocca2,3

  • 1Departments of Internal Medicine (Section of Vascular Medicine) and Biochemistry, Thrombosis Expertise Center, and CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, The Netherlands;

Annual Review of Pharmacology and Toxicology
|September 27, 2023
PubMed
Summary

Direct oral anticoagulants (DOACs) are widely used but have limitations. Careful patient selection and monitoring are crucial, especially for those with high-risk conditions or specific health factors.

Keywords:
antiplatelet agentsatrial fibrillationbleedingcancer-associated thrombosischronic kidney diseasedirect oral anticoagulantsdrug interactionsfactor XI inhibitorsreversal agentsvenous thromboembolism

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K

Related Experiment Videos

Last Updated: Jul 15, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.7K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Direct oral anticoagulants (DOACs) have become the standard for oral anticoagulation, replacing vitamin K antagonists like warfarin.
  • DOACs provide convenient fixed-dose anticoagulation for conditions including venous thromboembolism and stroke prevention in atrial fibrillation.

Purpose of the Study:

  • To review the efficacy and safety of DOACs in various patient populations.
  • To identify specific clinical scenarios where DOACs may be restricted or require cautious use.
  • To discuss the role of reversal agents and emerging anticoagulants.

Main Methods:

  • Literature review and synthesis of current evidence on DOAC use.
  • Analysis of DOAC effectiveness and safety in different patient groups.
  • Discussion of contraindications, special populations, and future therapeutic directions.

Main Results:

  • DOACs are not suitable for all patients, particularly those with antiphospholipid syndrome or mechanical heart valves.
  • Cancer-associated thrombosis patients may benefit from DOACs, but bleeding risk, especially with GI/urogenital tumors, needs careful assessment.
  • Elderly, frail patients, or those with obesity or chronic kidney disease require cautious DOAC administration and potential monitoring.

Conclusions:

  • DOACs offer significant advantages but require careful consideration of patient-specific factors and risks.
  • Reversal agents are available for emergencies, and novel anticoagulants like factor XI(a) inhibitors are under investigation.
  • Optimizing anticoagulant therapy for an aging and increasingly frail global population remains a key clinical challenge.